Table 3.
Pathology outcomes in both total and propensity-score-matched cohort
| Total cohort | Propensity-score-matched cohor | |||||
|---|---|---|---|---|---|---|
| Neoadjuvant therapy (n = 136) |
Upfront surgery (n = 1100) | P value | Neoadjuvant therapy (n = 94) | Upfront surgery (n = 94) | P value | |
| AJCC tumor stage T3/T4, n (%) | 86 (65.6) | 846 (79.4) | < 0.001 | 64 (68.1) | 63 (67.0) | 0.876 |
| Unknown | 5 | 34 | 0 | 0 | ||
| Lymph node stage, n (%) | 0.025 | 0.037 | ||||
| N0 | 64 (47.4) | 407 (37.5) | 45 (47.9) | 31 (33.0) | ||
| N1 | 71 (52.6) | 679 (62.5) | 49 (52.1) | 63 (67.0) | ||
| Unknown | 1 | 14 | 0 | 0 | ||
| Pathological stage, n (%) | < 0.001 | 0.005 | ||||
| Stage 0 | 1 (0.7) | 1 (0.1) | 0 (0.0) | 0 (0.0) | ||
| Stage 1A/1B | 28 (20.7) | 131 (12.1) | 18 (19.1) | 14 (14.9) | ||
| Stage 2A | 25 (18.5) | 258 (23.7) | 20 (21.3) | 16 (17.0) | ||
| Stage 2B | 64 (47.4) | 615 (56.5) | 44 (46.8) | 56 (59.6) | ||
| Stage 3 | 8 (5.9) | 40 (3.7) | 5 (5.3) | 3 (3.2) | ||
| Stage 4 | 9 (6.7) | 43 (4.9) | 7 (7.4) | 5 (5.3) | ||
| Unknown | 1 | 12 | 0 | 0 | ||
| Lymph nodes total, median (IQR) | 17 (10–25) | 17 (10–26) | 0.942 | 17 (10–27) | 22 (12–35) | 0.019 |
| Lymph nodes metastatic, median (IQR) | 1 (0–2) | 1 (0–3) | 0.003 | 1 (0–2) | 1 (0–3) | 0.101 |
| R0 resectiona, n (%) | 85 (63.4) | 673 (62.1) | 0.761 | 59 (64.1) | 64 (68.8) | 0.500 |
| Unknown | 2 | 16 | 0 | 0 | ||
| Lymphovascular involvement, n (%) | 64 (50.0) | 651 (63.8) | 0.002 | 45 (51.7) | 66 (72.5) | 0.004 |
| Unknown | 8 | 79 | 3 | 7 | ||
| Perineural involvement, n (%) | 95 (71.4) | 825 (79.8) | 0.026 | 70 (76.1) | 80 (87.9) | 0.037 |
| Unknown | 3 | 66 | 2 | 3 | ||
AJCC American Joint Committee on Cancer, 7th edition
aDefined as microscopic distance of ≥ 1 mm between margin and tumor